首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial
【2h】

All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial

机译:全反式维甲酸(ATRA)加奥沙利铂加5-氟尿嘧啶/亚叶酸(FOLFOX)与单独使用FOLFOX作为晚期肝细胞癌和肝外转移患者的姑息化疗:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAmong patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed. Prognosis has been quite poor as until recently there was no proven effective chemotherapy. Our group found that all-trans-retinoic acid (ATRA) could improve the efficacy of platinum in HCC in vivo and in vitro, thus we wish to validate the efficiency of ATRA in clinical practice.
机译:背景在所有肝细胞癌(HCC)患者中,有85%的患者在诊断时处于疾病晚期,无法进行治愈性治疗。预后很差,因为直到最近还没有证明有效的化学疗法。我们的小组发现,全反式维甲酸(ATRA)可以提高体内和体外HCC中铂的疗效,因此我们希望在临床实践中验证ATRA的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号